期刊文献+

探讨乳腺癌化疗中盐酸帕洛诺司琼的止吐治疗分析

下载PDF
导出
摘要 目的观察盐酸帕洛诺司琼在预防和治疗乳腺癌FAC或AC方案化疗中出现的消化道不良反应的有效性。方法将50例接受FAC或AC方案化疗的乳腺癌患者随机分成两组,化疗前实验组静脉缓慢注射盐酸帕洛诺司琼0.25mg,对照组静脉缓慢注射盐酸格拉司琼3mg止吐。观察二者对患者化疗后出现的急性呕吐、延迟性呕吐等不良反应的控制情况并做比较。结果实验组和对照组化疗后对急性呕吐(24小时内)止吐效果相近,差异无显著性(94.56%vs.91.28%,P>0.05);实验组中对化疗后出现的延迟性呕吐(24小时~7天)止吐效果明显优于对照组,2组有显著差异性(89.26%vs.60.97%,P<0.05)。结论盐酸帕洛诺司琼能有效控制乳腺癌FAC或AC方案化疗中出现的急性呕吐、延迟性呕吐、恶心。
出处 《求医问药(下半月刊)》 2012年第8期440-441,共2页 Seek Medical and Ask The Medicine
  • 相关文献

参考文献5

  • 1TOMEK R,VRDOLJAK E,VRBANEC D. Croatian guideliness for prevention of chemotherapy induced nausea and vomiting[J].Lijecnicki Vjesnik,2009,(3-4):49-53.
  • 2孙燕;石远凯.临床肿瘤内科学[M]北京:人民卫生出版社,20079.
  • 3Andrew PLR,Rapeport W G,Sanger G J. Neuropharm acology o f emesis induced by anticancer therapy[J].Trend s in Pharma col Sci,2008,(09):334.
  • 4Stolt z R,Pa risi S,Shah A. Phara cokinetics,metabolism and excret ion of intravenous Opalopooet ron in healthy human volunteers[J].Biopharm Drug Disps,2010,(08):329.
  • 5李志强,徐建明,刘端祺,张贺龙,王宝成,张沂平,欧阳学农,陈正堂,陶敏,高亚杰,王岩,李晓玲,刘烈军.盐酸帕洛诺司琼预防中重度化疗致吐药引起恶心呕吐的Ⅱ期临床研究[J].临床肿瘤学杂志,2009,14(6):487-490. 被引量:36

二级参考文献8

  • 1陈艳,丁莉坤,孟玲燕,丁黎,杨林,文爱东.盐酸帕洛诺司琼注射液人体药动学研究[J].中国新药杂志,2007,16(10):806-809. 被引量:14
  • 2Gralla R, Lichinitser M, Van Der Vegt S, et al. Palonosetron improves prevention of chemotherapy-induced nausea and vomiting following moderately emetogenic chemotherapy: results of a double-blind randomized phase Ⅲ trial comparing single doses of palonosetron with ondansetron [ J ]. Ann Oncol, 2003,14 (10) : 1570 - 1577.
  • 3Aapro MS. Palonosetron as an anti-emetic and anti-nausea agent in oncology[ J]. Ther Clin Risk Manag, 2007,3 (6) : 1009 - 1020.
  • 4Siddiqui MA, Scott LJ. Palonosetron [ J ]. Drugs, 2004,64 (10) :1125 - 1132.
  • 5Stohz R, Cyong JC, Shaha, et al. Pharmacokinetic and safety evaluation of palonosetron, a 5-hydroxytryptamine-3 receptor antagonist,in U. S. and Japanese healthy subjects[J]. J Clin Pharmacol, 2004,44(5 ) :520 -531.
  • 6Eisenberg P, Mackintosh FR, Ritch P, et al. Efficacy, safety and pharmacokinetics of palonosetron in patients receiving highly emetogenic cisplatin-based chemotherapy: a dose-ranging clinical study[J]. Ann Oncol, 2004,15(2) :330-337.
  • 7Hunt TL, Gallagher SC, Cullen MT, et al. Evaluation of safety and pharmacokinetics of consecutive multiple-day dosing of palonosetron in healthy subjects [ J ]. J Clin Pharmacol, 2005,45 (5) :589 -596.
  • 8Aapro MS, Grunberg SM, Manikhas GM, et al. A phase Ⅲ, double-blind, randomized trial of palonosetron compared with ondansetron in preventing chemotherapy-induced nausea and vomiting following highly emetogenic chemotherapy [ J ]. Ann Oncol, 2006,17(9) :1441-1449.

共引文献35

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部